Clinical Study Results Of EarlySense's EverOn(R) Patient Supervision System

Main Category: Medical Devices / Diagnostics
Article Date: 01 Oct 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions

EarlySense, developer of continuous supervision systems for hospital and home use, announced today that the results of a clinical study of the EverOn system conducted at the Sourasky Medical Center in Tel Aviv will be presented by Drs. Patrick Sorkine, Nimrod Adi and Yossi Ben-Ari at the European Respiratory Society in Berlin on October 6, 2008.

"We are looking forward to sharing our clinical findings with the participants of this conference and to answering any potential questions," said Mr. Avner Halperin, CEO of EarlySense.

EverOn® is a continuous, contact-free, patient supervision system that measures patient parameters and alerts upon patient change in clinical condition. There are no leads or cuffs to connect to the patient, who has complete freedom of movement and is not burdened by any irritating attachments. EverOn detects heart and respiration rates as well as bed entries and exits, and patient movement. The device sounds an alert when a pre-set parameter threshold is crossed. EverOn also displays and records real time data on a continuous trend-line. The trend line display is designed to assist clinicians in predicting the progression of a patient's health and consequently avert critical events.

"We are excited to see clinicians testing the EverOn system in real life usage scenarios and reporting their results. We expect that this trend will continue and increase in its extent as patient supervision systems become the standard of care in hospitals over the next few years," said Mr. Halperin.

EarlySense also announced today that the interim results of a large clinical study performed with the EverOn system at Sheba Medical Center were presented on September 15, 2008 at the 6th Autoimmunity Congress in Porto, Portugal. The address was delivered by Dr. Eyal Zimlichman of the Department of Internal Medicine B, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel. The title of the presentation was "Continuous Monitoring of Respiratory Diseases in Hospitalized Patients: Can we Predict Outcomes?"

Dr. Zimlichman said, "I believe the answer to this question is yes. From our experience, we would indeed suggest that continuous heart rate and respiration rate supervision should be used with patients with respiratory conditions to alert for acute deterioration and provide clinicians with ongoing data that is correlated with a patient's clinical status and consequently predicts health outcomes."

About EarlySense

EarlySense is bringing to market a pioneering technology designed to advance proactive and preventive patient supervision to enable better patient outcomes. The flagship product, EverOn, is an automatic, continuous, contact-free patient supervision device that follows and documents a patient's movement and basic vital signs. The system is currently being evaluated clinically at several medical centers in the USA and Israel. EarlySense was founded in 2004 by experienced entrepreneurs and is headquartered in Ramat-Gan, Israel. For additional information, please visit http://www.earlysense.com or contact Marjie Hadad, Media Liaison, at +972-54-536-5220 or marjie.hadad@earlysense.com.

EarlySense